487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
| Autor: | Chai, C.S. 1, Liam, C.K. 2, Po Lin, O. 3, Pang, Y.K. 4, Ho, G.F. 5, Alip, A. 6, Wong, C.K. 2, Poh, M.E. 2, Tan, J.L. 2 |
|---|---|
| Zdroj: | In Annals of Oncology November 2019 30 Supplement 9:ix164-ix164 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|